A Transformation in the Making - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Transformation in the Making
The economic case for personalized medicine offers a solution to the industry's recent woes.


Pharmaceutical Technology


Patricia Van Arnum
The sobering news from a recent IMS Health analysis that the US prescription pharmaceutical market grew only 3.8% in 2007, its lowest growth rate since 1961, raises a fundamental question, "What will the pharmaceutical industry do?"

Sidney Taurel, retiring CEO and chairman of Eli Lilly (Indianapolis, IN), offered his vision of the pharmaceutical industry, including the role "tailored therapeutics" will play in the future. Taurel spoke at the Drug, Chemical and Associated Technologies Association's educational program in New York last month.

He said the term "tailored therapeutics" was more fitting than "personalized medicine" because it encompasses not only a targeted medicinal approach, but also a focus and segmentation throughout drug development and commercialization.

A common perception is that the erosion of the blockbuster-drug model and a new business case based on personalized medicine bodes ominously for the bottom line of the pharmaceutical industry. But is this the case? Such a transformation represents a shift from earning a relatively small market share of a very large pie under the blockbuster model to gaining a relatively large share of a more segmented pie with a tailored therapeutic. Given the improved efficacy of a tailored therapeutic, the rate of repeat prescribing and patient compliance may also increase, further creating economic value. Also, the cost of drug development could decrease as a result of smaller, more focused clinical trials, the ability, in some cases, to eliminate unpromising drug candidates earlier in clinical development, overall shorter development times, and the opportunity to develop secondary indications earlier: all a byproduct of more targeted drug development.

Is personalized medicine a viable solution for the pharmaceutical industry? Offer your views on this and other topics at our blog, PharmTech Talk, at blog.pharmtech.com.

Patricia Van Arnum is a senior editor with Pharmaceutical Technology,

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here